Vonlerolizumab

DB16352Investigational

Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Also known as: Immunoglobulin g1-kappa, anti-(homo sapiens tnfrsf4(tumor necrosis factor receptor (tnfr) superfamily member 4, act35, ox40, cd134)), humanized monoclonal antibody · Immunoglobulin g1-kappa, anti-(human tumor necrosis factor receptor superfamily member 4 (act35 antigen, ox40l receptor, cd134 antigen))humanized mouse monoclonal antibody: .gamma.1 heavy chain (1-447) (humanized mouse vh (homo sapiens ighv1-46*01 (81%) · Pogalizumab
Code names: MOXR-0916 · R0-7021608

Resolves to

Compound

UNIIC78148TF1DCAS1638935-72-4

Targets

P43489TNFRSF4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vonlerolizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account